Helix BioPharma Corp. (TSX: HBP, OTC: HBPCF, FRANKFURT: HBP0) announced the voting results from its Annual General and Special Meeting held on January 30, 2026. Shareholders representing 81.03% of the company's issued and outstanding shares voted, with overwhelming approval for all items of business.
All four director nominees—Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube—were re-elected with 99.99% of votes cast in favor. The appointment of Clearhouse LLP as auditor was also approved with 99.99% support. Additionally, shareholders authorized an amendment to the company's articles to effect a consolidation of common shares at a ratio of up to 5 pre-consolidation shares for 1 post-consolidation share, with the board determining the final ratio. This resolution passed with 99.99% of votes in favor.
The share consolidation is a strategic move that could potentially increase the stock price and meet exchange listing requirements. Helix BioPharma is a clinical-stage oncology company developing therapies for hard-to-treat cancers. Its lead candidate, Tumour Defence Breaker L-DOS47, is an antibody-enzyme conjugate targeting CEACAM6-expressing solid tumors and has completed Phase Ib studies in non-small cell lung cancer.
Details of the meeting results will be filed on SEDAR+ at www.sedarplus.com. The company emphasizes the importance of these governance decisions in advancing its pipeline and maintaining shareholder support.
Helix BioPharma is listed on the TSX, OTC PINK, and Frankfurt Stock Exchange. Further information is available on its website at https://www.helixbiopharma.com/.
